Learning Objectives
At the conclusion of this activity, participants should be able to:

• Describe the similarities and differences among biologic agents in achieving rapid induction and
long-term, sustained remission in patients with Crohn’s disease (CD)

• Explain the clinical value of early use of biologic therapy in CD

• Define practical considerations for the optimal use of biologics in CD, including patient selection, timing of therapy, dosing, and use of biologics alone or in combination with immunosuppressive agents

• Describe the long-term safety of biologics and the benefit-risk profile of these agents

Educational Method
Monograph

Target Audience
This program has been designed for physicians
and other health care professionals involved in the management of patients with CD.

CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies
of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship
of Chicago Medical School at Rosalind Franklin University of Medicine and Science and Scientific Frontiers, Inc. Chicago Medical School at Rosalind Franklin University of Medicine and Science is accredited by the ACCME to provide continuing medical education for physicians.

Chicago Medical School at Rosalind Franklin University of Medicine and Science designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Stefan Schreiber, MD: Consultant: Abbott, Bristol-Myers Squibb, Centocor, Essex Pharmaceuticals, Schering-Plough, UCB Celltech; Advisory Board: Abbott, Bristol-Myers Squibb, Centocor, Chemocentryx, Essex Pharma, Schering-Plough, UCB Celltech; Speakers’ Bureau: Abbott, Centocor, Essex Pharma, Schering-Plough, UCB Celltech; Stockholder: CONARIS Research Institute AG.

Remo Panaccione, MD: Research Support:
Abbott, Bristol-Myers Squibb, Centocor, Elan Pharmaceuticals, Millennium Pharmaceuticals, Procter & Gamble, Schering-Plough; Consultant: Abbott, AstraZeneca, Bristol-Myers Squibb, Centocor, Elan Pharmaceuticals, GlaxoSmithKline, Ferring, Procter & Gamble, Schering-Plough, UCB Pharma; Advisory Board: Abbott, Elan Pharmaceuticals, Ferring, Schering-Plough, Shire; Speakers’ Bureau: Abbott, AstraZeneca, Axcan, Byk Solvay, Centocor, Janssen, Procter & Gamble, Prometheus.

Bruce E. Sands, MD, MS: Research Support: Abbott, Centocor; Consultant: Abbott, Biogen IDEC, Centocor, Elan Pharmaceuticals, UCB Pharma; Advisory Board: Abbott, Centocor, Elan Pharmaceuticals, UCB Pharma; Speakers’ Bureau: Abbott, Centocor, Elan Pharmaceuticals, UCB Pharma.

Support
Support for this activity has been provided through an educational grant from Abbott.

Expiration Date
CME credits for this monograph are available from the release date (August 2008) through August 31, 2009.

Post-test
After thoroughly reading this monograph, answer
each question on the post-test by marking the letter
corresponding to the correct answer on the post-test answer form. For scoring and credit, please complete the rest of the information on the evaluation form.

n For CME credit fax to 847-578-3320 or mail to the following address:
Elsa Kurien, MA, M.Ed.
CME Director, Office of Clinical Affairs
The Chicago Medical School at Rosalind Franklin University of Medicine & Science
3333 Green Bay Road
North Chicago, IL 60064

Certificates of CME credit will be issued by The Chicago Medical School at Rosalind Franklin University of Medicine